Symbols / CVM $1.30 +8.33% CEL-SCI Corporation

Healthcare • Biotechnology • United States • ASE
CVM Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Geert R. Kersten Esq.
Exch · Country ASE · United States
Market Cap 18.84M
Enterprise Value 13.34M
Income -23.81M
Sales —
FCF (ttm) -8.94M
Book/sh 1.38
Cash/sh 0.78
Employees —
Insider 10d —
IPO Dec 08, 1983
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.41
PEG 1.12
P/S —
P/B 0.94
P/C —
EV/EBITDA -0.63
EV/Sales —
Quick Ratio 1.25
Current Ratio 1.40
Debt/Eq 81.75
LT Debt/Eq —
EPS (ttm) -3.70
EPS next Y -0.92
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-12
Earnings (prior) 2026-02-12
ROA -59.90%
ROE -212.12%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 14.49M
Shs Float 7.94M
Insider Own 5.46%
Instit Own 5.33%
Short Float 8.40%
Short Ratio 10.45
Short Interest 708.41K
52W High 13.48
vs 52W High -90.36%
52W Low 0.89
vs 52W Low 46.07%
Beta 0.71
Impl. Vol. —
Rel Volume 7.52
Avg Volume 255.02K
Volume 1.92M
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.20
Price $1.30
Change 8.33%
About

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.30
Latest analyst target
3. DCF / Fair value
$-11.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.30
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-07-12 reit EF Hutton Buy → Buy $10
2023-03-09 reit EF Hutton — → Buy $10
2022-12-29 main EF Hutton — → Buy $16
2022-04-07 init EF Hutton — → Buy $17
2020-01-13 init HC Wainwright & Co. — → Buy $18
2013-02-20 init Taglich Brothers — → Speculative Buy —
2013-02-13 init Chardan Capital — → Buy $1
2013-01-14 init Laidlaw & Co. — → Buy $1
News
RSS: Latest CVM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-13 KERSTEN GEERT R Chief Executive Officer — 100,000 $1.19 $119,000
2026-03-31 TALOR EYAL Officer — 747 $3.21 $2,398
2026-03-31 KERSTEN GEERT R Chief Executive Officer — 1,682 $3.21 $5,399
2026-03-31 PRICHEP PATRICIA B Chief Financial Officer — 1,336 $3.21 $4,289
2026-01-22 KERSTEN GEERT R Chief Executive Officer — 38,023 $5.26 $200,001
2025-12-31 TALOR EYAL Officer — 456 $5.26 $2,399
2025-12-31 KERSTEN GEERT R Chief Executive Officer — 998 $5.26 $5,249
2025-12-31 PRICHEP PATRICIA B Chief Financial Officer — 815 $5.26 $4,287
2025-12-04 KERSTEN GEERT R Chief Executive Officer — 8,389 $5.96 $49,998
2025-09-30 TALOR EYAL Officer — 260 $9.20 $2,392
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
24.81
-5.85%
26.35
-16.28%
31.48
-12.72%
36.06
Research And Development
15.89
-12.52%
18.16
-19.18%
22.47
-11.37%
25.36
Selling General And Administration
8.92
+8.93%
8.19
-9.03%
9.00
-15.90%
10.71
General And Administrative Expense
8.92
+8.93%
8.19
-9.03%
9.00
-15.90%
10.71
Other Gand A
8.92
+8.93%
8.19
-9.03%
9.00
-15.90%
10.71
Total Expenses
24.81
-5.85%
26.35
-16.28%
31.48
-12.72%
36.06
Operating Income
-24.81
+5.85%
-26.35
+16.28%
-31.48
+12.72%
-36.06
Total Operating Income As Reported
-24.81
+5.85%
-26.35
+16.28%
-31.48
+12.72%
-36.06
EBITDA
-20.88
+5.98%
-22.21
+19.43%
-27.56
+13.31%
-31.79
Normalized EBITDA
-20.88
+5.98%
-22.21
+19.43%
-27.56
+14.30%
-32.16
Reconciled Depreciation
3.89
-2.12%
3.97
+0.27%
3.96
+3.38%
3.83
EBIT
-24.76
+5.40%
-26.17
+16.96%
-31.52
+11.51%
-35.62
Total Unusual Items
—
—
—
0.37
Total Unusual Items Excluding Goodwill
—
—
—
0.37
Net Income
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Pretax Income
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Net Non Operating Interest Income Expense
-0.65
+12.97%
-0.75
-10.40%
-0.68
+37.52%
-1.08
Interest Expense Non Operating
0.65
-12.97%
0.75
+10.40%
0.68
-37.52%
1.08
Net Interest Income
-0.65
+12.97%
-0.75
-10.40%
-0.68
+37.52%
-1.08
Interest Expense
0.65
-12.97%
0.75
+10.40%
0.68
-37.52%
1.08
Other Income Expense
0.05
-73.20%
0.18
+515.02%
-0.04
-109.66%
0.44
Other Non Operating Income Expenses
0.05
-73.20%
0.18
+515.02%
-0.04
-156.07%
0.08
Gain On Sale Of Security
—
—
—
0.37
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Net Income From Continuing Operation Net Minority Interest
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Net Income From Continuing And Discontinued Operation
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Net Income Continuous Operations
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Normalized Income
-25.41
+5.61%
-26.92
+16.38%
-32.19
+13.15%
-37.07
Net Income Common Stockholders
-25.41
+7.86%
-27.58
+14.79%
-32.37
+13.99%
-37.63
Otherunder Preferred Stock Dividend
0.00
-100.00%
0.66
+284.41%
0.17
-81.54%
0.93
Diluted EPS
-6.27
+59.05%
-15.31
+30.09%
-21.90
+16.09%
-26.10
Basic EPS
-6.27
+59.05%
-15.31
+30.09%
-21.90
+16.09%
-26.10
Basic Average Shares
4.06
+125.13%
1.80
+21.50%
1.48
+3.08%
1.44
Diluted Average Shares
4.06
+125.13%
1.80
+21.50%
1.48
+3.08%
1.44
Diluted NI Availto Com Stockholders
-25.41
+7.86%
-27.58
+14.79%
-32.37
+13.99%
-37.63
Average Dilution Earnings
—
—
—
0.00
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
28.16
+4.31%
26.99
-11.58%
30.53
-39.58%
50.52
Current Assets
11.60
+91.49%
6.06
-12.47%
6.92
-72.80%
25.44
Cash Cash Equivalents And Short Term Investments
10.95
+131.17%
4.74
+14.29%
4.15
-81.71%
22.67
Cash And Cash Equivalents
10.95
+131.17%
4.74
+14.29%
4.15
-81.71%
22.67
Other Short Term Investments
—
—
—
0.00
Receivables
—
—
—
0.00
Accounts Receivable
—
—
—
0.00
Inventory
0.30
-70.26%
1.02
-54.63%
2.25
+12.31%
2.00
Raw Materials
0.30
-70.26%
1.02
-54.63%
2.25
+12.31%
2.00
Prepaid Assets
0.34
+14.04%
0.30
-43.27%
0.52
-31.16%
0.76
Total Non Current Assets
16.56
-20.90%
20.94
-11.32%
23.61
-5.89%
25.09
Net PPE
12.90
-24.00%
16.98
-19.23%
21.02
-14.94%
24.71
Gross PPE
24.96
-7.70%
27.04
-6.63%
28.96
-5.23%
30.56
Accumulated Depreciation
-12.06
-19.79%
-10.07
-26.71%
-7.94
-35.82%
-5.85
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.10
+0.00%
0.10
+5.33%
0.10
+0.00%
0.10
Other Properties
10.93
-16.00%
13.01
-12.89%
14.94
-11.69%
16.92
Leases
13.92
+0.00%
13.92
+0.00%
13.92
+2.81%
13.54
Goodwill And Other Intangible Assets
0.12
-27.58%
0.17
-16.29%
0.20
-6.83%
0.21
Other Intangible Assets
0.12
-27.58%
0.17
-16.29%
0.20
-6.83%
0.21
Non Current Prepaid Assets
2.32
+0.00%
2.32
+0.00%
2.32
0.00
Other Non Current Assets
1.22
-17.42%
1.48
+1875.98%
0.07
-54.55%
0.16
Total Liabilities Net Minority Interest
12.20
-13.64%
14.12
-18.42%
17.31
-5.70%
18.36
Current Liabilities
5.13
+11.15%
4.62
-17.37%
5.59
+19.77%
4.66
Payables And Accrued Expenses
2.69
+13.12%
2.38
-34.25%
3.62
+23.34%
2.93
Payables
1.98
+9.17%
1.81
-29.42%
2.57
+22.84%
2.09
Accounts Payable
1.06
-26.73%
1.45
-27.93%
2.01
+24.19%
1.62
Other Payable
0.92
+152.29%
0.36
-34.80%
0.56
+18.19%
0.47
Current Accrued Expenses
0.71
+25.75%
0.57
-46.07%
1.05
+24.58%
0.84
Current Debt And Capital Lease Obligation
2.44
+9.06%
2.24
+13.65%
1.97
+13.73%
1.73
Current Capital Lease Obligation
2.44
+9.06%
2.24
+13.65%
1.97
+13.73%
1.73
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
7.07
-25.67%
9.51
-18.92%
11.73
-14.38%
13.70
Long Term Debt And Capital Lease Obligation
6.94
-26.01%
9.38
-19.12%
11.60
-14.51%
13.57
Long Term Capital Lease Obligation
6.94
-26.01%
9.38
-19.12%
11.60
-14.51%
13.57
Other Non Current Liabilities
0.12
+0.00%
0.12
+0.00%
0.12
+0.00%
0.12
Stockholders Equity
15.96
+24.01%
12.87
-2.63%
13.21
-58.91%
32.16
Common Stock Equity
15.96
+24.01%
12.87
-2.63%
13.21
-58.91%
32.16
Capital Stock
0.08
+276.93%
0.02
-95.52%
0.47
+9.15%
0.43
Common Stock
0.08
+276.93%
0.02
-95.52%
0.47
+9.15%
0.43
Preferred Stock
0.00
0.00
0.00
—
Share Issued
8.02
+276.99%
2.13
+34.51%
1.58
+9.15%
1.45
Ordinary Shares Number
8.02
+276.99%
2.13
+34.51%
1.58
+9.15%
1.45
Additional Paid In Capital
555.30
+5.40%
526.86
+5.41%
499.83
+2.71%
486.63
Retained Earnings
-539.42
-4.94%
-514.01
-5.53%
-487.09
-7.08%
-454.90
Total Equity Gross Minority Interest
15.96
+24.01%
12.87
-2.63%
13.21
-58.91%
32.16
Total Capitalization
15.96
+24.01%
12.87
-2.63%
13.21
-58.91%
32.16
Working Capital
6.47
+349.03%
1.44
+8.05%
1.33
-93.58%
20.77
Invested Capital
15.96
+24.01%
12.87
-2.63%
13.21
-58.91%
32.16
Total Debt
9.38
-19.26%
11.62
-14.37%
13.57
-11.31%
15.30
Capital Lease Obligations
9.38
-19.26%
11.62
-14.37%
13.57
-11.31%
15.30
Net Tangible Assets
15.84
+24.69%
12.70
-2.42%
13.02
-59.26%
31.95
Tangible Book Value
15.84
+24.69%
12.70
-2.42%
13.02
-59.26%
31.95
Derivative Product Liabilities
—
—
—
—
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-17.12
+8.99%
-18.81
+17.67%
-22.85
-25.26%
-18.24
Cash Flow From Continuing Operating Activities
-17.12
+8.99%
-18.81
+17.67%
-22.85
-25.26%
-18.24
Net Income From Continuing Operations
-25.41
+5.61%
-26.92
+16.38%
-32.19
+12.28%
-36.70
Depreciation Amortization Depletion
3.89
-2.12%
3.97
+0.27%
3.96
+3.38%
3.83
Depreciation And Amortization
3.89
-2.12%
3.97
+0.27%
3.96
+3.38%
3.83
Other Non Cash Items
0.35
+6981.33%
0.00
-68.13%
0.02
-86.02%
0.11
Stock Based Compensation
2.88
-46.07%
5.35
-25.21%
7.15
-42.23%
12.38
Asset Impairment Charge
0.02
0.00
0.00
-100.00%
0.03
Operating Gains Losses
—
—
—
-0.37
Gain Loss On Investment Securities
—
—
—
-0.37
Change In Working Capital
1.16
+195.60%
-1.21
+31.80%
-1.78
-171.59%
2.48
Change In Receivables
—
—
—
0.05
Change In Inventory
0.97
+664.09%
-0.17
-10.13%
-0.16
+1.70%
-0.16
Change In Prepaid Assets
-0.04
-158.55%
0.07
-52.17%
0.15
-9.37%
0.17
Change In Payables And Accrued Expense
0.23
+120.78%
-1.11
-302.11%
0.55
-2.30%
0.56
Change In Accrued Expense
0.12
+126.33%
-0.46
-321.40%
0.21
+1338.27%
-0.02
Change In Payable
0.11
+116.89%
-0.65
-290.49%
0.34
-40.80%
0.58
Change In Account Payable
-0.44
+3.88%
-0.46
-278.63%
0.26
-31.22%
0.37
Change In Other Working Capital
-0.00
-581.21%
0.00
+100.03%
-2.32
-221.58%
1.91
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
-0.04
+64.74%
-0.11
+70.97%
-0.37
-106.78%
5.49
Cash Flow From Continuing Investing Activities
-0.04
+64.74%
-0.11
+70.97%
-0.37
-106.78%
5.49
Net PPE Purchase And Sale
-0.04
+59.83%
-0.09
+73.78%
-0.36
+43.27%
-0.64
Purchase Of PPE
-0.04
+59.83%
-0.09
+73.78%
-0.36
+43.27%
-0.64
Capital Expenditure
-0.04
+64.74%
-0.11
+70.97%
-0.37
+43.65%
-0.66
Capital Expenditure Reported
0.00
+100.00%
-0.01
-27.40%
-0.01
+54.40%
-0.02
Net Investment Purchase And Sale
—
—
0.00
-100.00%
6.15
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
0.00
-100.00%
6.15
Financing Cash Flow
23.37
+19.79%
19.51
+315.64%
4.69
+835.31%
-0.64
Cash Flow From Continuing Financing Activities
23.37
+19.79%
19.51
+315.64%
4.69
+835.31%
-0.64
Net Issuance Payments Of Debt
-2.01
-13.41%
-1.77
-13.64%
-1.56
-160.06%
-0.60
Issuance Of Debt
0.35
-22.22%
0.45
0.00
-100.00%
0.79
Repayment Of Debt
-2.36
-6.20%
-2.22
-42.48%
-1.56
-12.55%
-1.39
Long Term Debt Issuance
—
—
0.00
-100.00%
0.79
Long Term Debt Payments
-2.01
-13.41%
-1.77
-13.64%
-1.56
-12.55%
-1.39
Net Long Term Debt Issuance
-2.01
-13.41%
-1.77
-13.64%
-1.56
-160.06%
-0.60
Short Term Debt Issuance
0.35
-22.22%
0.45
0.00
—
Short Term Debt Payments
-0.35
+22.22%
-0.45
0.00
—
Net Short Term Debt Issuance
0.00
0.00
0.00
—
Net Common Stock Issuance
28.51
+20.53%
23.66
+261.02%
6.55
0.00
Proceeds From Stock Option Exercised
—
0.00
-100.00%
0.45
+241.29%
0.13
Net Other Financing Charges
-3.13
-31.90%
-2.37
-218.23%
-0.74
-339.62%
-0.17
Changes In Cash
6.22
+949.10%
0.59
+103.20%
-18.53
-38.38%
-13.39
Beginning Cash Position
4.74
+14.29%
4.15
-81.71%
22.67
-37.13%
36.06
End Cash Position
10.95
+131.17%
4.74
+14.29%
4.15
-81.71%
22.67
Free Cash Flow
-17.16
+9.31%
-18.92
+18.52%
-23.22
-22.85%
-18.90
Interest Paid Supplemental Data
0.77
-16.82%
0.92
-13.06%
1.06
-8.17%
1.16
Common Stock Issuance
28.51
+20.53%
23.66
+261.02%
6.55
0.00
Issuance Of Capital Stock
28.51
+20.53%
23.66
+261.02%
6.55
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category